Seaweed Extract Emerges as Potential Lymphoma Treatment

In some unexpected news, seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic in Jordan.
What makes seaweed so special? Apparently, it contains a chemical called fucoidan, which is a sulfate polysaccharide similar to heparin in structure, and that has been reported to fight tumors in mice and in some cell lines, one of the study's authors, Mohammad Irhimeh said at the conference.
Irhimeh, from the Hashemite University in Jordan, worked with colleagues from the University of California, Berkley and the Royal Hobart Hospital in Australia on the project. The researchers say they found fucoidans had an inhibitory effect on the growth of lymphoma cell lines, while keeping healthy cells intact. The researchers also noted a significant pattern of activity in the genes known to be linked with apoptosis, or cell death, in lymphoma.
The scientists used commercially available seaweed extract for the experiment.
SOURCE: American Association for Cancer Research, news release, March 10, 2010

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap